Valeant Pharmaceuticals International, Inc. (NYSE: VRX)

It operates through two segments: Developed markets and Emerging markets. New York-based Tiaa Cref Investment Mgmt Llc has invested 0.01% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has "Underperform" rating given on Tuesday, June 20 by Mizuho. The Regal Investment Advisors Llc holds 37,463 shares with $2.91 million value, down from 41,954 last quarter.

Trading volume for Valeant Pharmaceuticals Interna was 4,180K on Tuesday. (NYSE:VRX) tinted loss of -0.28% (-0.04 points) to US$14.42. The stock exchanged hands with 5,479,936 numbers of shares compared to its average daily volume of 12.02M shares. Moreover, Evercore Wealth Limited Liability Company has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). It has underperformed by 65.21% the S&P500.

Pomelo Capital Llc increased Penney J C Inc (Put) (NYSE:JCP) stake by 4.59M shares to 4.97M valued at $23.10 million in 2017Q2. It also upped Ishares Tr (EMB) stake by 2,877 shares and now owns 13,152 shares. Valeant Pharmaceuticals Intl had a positive return on equity of 43.81% and a negative net margin of 22.17%. The stock has "Buy" rating by Longbow on Friday, August 14. On Monday, November 2 the stock rating was downgraded by Goldman Sachs to "Neutral". The company was maintained on Wednesday, November 11 by Stifel Nicolaus. The rating was maintained by Cantor Fitzgerald on Monday, September 25 with "Buy". Canaccord Genuity maintained it with "Hold" rating and $40 target in Wednesday, March 16 report.

08/10/2017 - Valeant Pharmaceuticals International, Inc. had its "market perform" rating reiterated by analysts at BMO Capital Markets.

Investors sentiment decreased to 1.08 in 2017 Q2.

Valeant Pharmaceuticals International, Inc. was covered by a number of analysts recently, 2 rated the stock as Buy, 1 rated Outperform, 13 rated Hold, 5 gave an Underperform and 0 rated sell. It turned negative, as 53 investors sold VRX shares while 76 reduced holdings. 49 funds opened positions while 90 raised stakes. The funds in our partner's database now possess: 171.89 million shares, up from 169.40 million shares in 2017Q1. Market capitalization is calculated by multiplying a company's shares outstanding by the current market price of one share. Oppenheimer Incorporated holds 0.01% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) or 27,727 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 259,274 shares or 0.2% of the stock. Rbf Capital Limited Liability Com holds 0.3% or 131,100 shares. 606.01 million shares or 2.56% less from 621.93 million shares in 2017Q1 were reported. Asset Management invested in 0.01% or 20,486 shares. Balyasny Asset Management LLC owned approximately 0.05% of Valeant Pharmaceuticals International worth $3,037,000 at the end of the most recent reporting period. Zurcher Kantonalbank (Zurich Cantonalbank) owns 110,880 shares or 0.02% of their U.S. portfolio. Nexus Inv has invested 0.1% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Tuesday, November 3. Sei Invests Com has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). 200,096 are held by Aviva Plc. Piper Jaffray maintained the stock with "Sell" rating in Wednesday, July 12 report.

Spain threatens to suspend Catalonia's autonomy in crisis
If he says he did not declare it, then far-left party CUP would probably withdraw its support for his minority government. It is not yet clear if the Catalan government will answer the requirement but it now faces a conundrum, analysts say.

Carmakers hit in Japan steel scandal
Companies from Japan and overseas are investigating whether safety of their products has been compromised. It was unclear what the impact would be on earnings, the company said in a statement.

Scientists find $1.8 million worth of gold in Swiss wastewater
The report says the study focused primarily on the fluxes and mass balances, rather than recovery value. The lost gold is worth almost $2 million at current prices.

Since January 1, 0001, it had 1 insider purchase, and 0 insider sales for $278,000 activity. The Company's activities consist of purchasing raw materials, formulating and manufacturing products and selling the finished products.

Analysts await GNC Holdings Inc (NYSE:GNC) to report earnings on October, 26. Eagle Asset Management reported 0.07% in Centerstate Bank Corp (NASDAQ:CSFL).

The company's Average Earnings Estimate for the Current Fiscal quarter is $0.95, according to consensus of 15 analysts. This translates into $334.55 million profit for VRX giving the stock a 3.78 P/E. Equities research analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year. It is down 0.00% since October 11, 2016 and is. San Francisco Sentry Invest Group (Ca) holds 4,000 shares. Westpac Bk owns 20,824 shares or 0% of their United States portfolio.

According to the Recommendation Trends of the stock polled by Finviz, the company has a consensus recommendation of 3 out of the scale from 1 to 5, where 1 stands for Buy and 5 means Sell. The stock witnessed 1.9% gains, -14.89% declines and 51.41% gains for the 1-month, 3-month and 6-month period, respectively.

Gramercy Funds Management Llc decreased Valeant Pharmaceuticals Intl (VRX) stake by 85.7% reported in 2017Q2 SEC filing.

Latest News